Characterization of New Human Models of Non-histaminergic Itch

Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor

In this experiment the investigators would like to test a new new human itch model based on papain, and to characterize the sensory quality and temporary aspects of papain skin prick test (SPT) in comparison to the inactivated-cowhage delivery system.

Study Overview

• Status: Completed
• Conditions: Itch; Papain; Skin Prick Test (SPT)
• Intervention / Treatment: Drug: Papain 10 µg; Drug: Papain 50 µg; Drug: Papain 100 µg; Other: Vehicle; Drug: Papain 1 SPT; Drug: Papain 5 SPT; Drug: Papain 25 SPT; Other: Cowhage

Detailed Description

The most used model of non-histaminergic itch is cowhage but this models presents several problems, such us the impossibility of standardizing the amount of the spicules inserted in the skin and the difficulty of obtaining the substance. These aspects bring us the necessity to find a new and more standardized model of non-histaminergic itch.

Papain is a cysteine protease extracted from papaya plant that is known to cause itch if applied to the skin. For these reasons the investigators would like to test a new new human itch model based on papain, and to characterize the sensory quality and temporary aspects of papain skin prick test (SPT) in comparison to the inactivated-cowhage delivery system.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Denmark
  • Nordjylland
    • Aalborg, Nordjylland, Denmark, 9000
      • Aalborg University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy men and women
• 18-60 years
• Speak and understand English

Exclusion Criteria:

• Pregnancy or lactation
• Drug addiction defined as any use of cannabis, opioids or other addictive drugs
• Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.).
• Lack of ability to cooperate
• Current use of medications that may affect the trial such as antihistamines, antipsychotics and pain killers, as well as systemic or topical steroids.
• Skin diseases
• Moles, scars or tattoos in the area to be treated or tested.
• Hypersensitivity to papaya and mango fruit, cashew nuts, rubber latex
• Consumption of alcohol or painkillers 24 hours before the study days and between these
• Acute or chronic pain
• Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Papain dosage; In the 1st session, each of the middle forearms of the subject will be divided into two squared areas (4x4 cm). The two areas will be located 4 cm apart. Three areas will be exposed to 10, 50 or 100 µg of papain, while the last area will be used as control (exposed to a vehicle).	Drug: Papain 10 µg; The area will be exposed to 10 µg of papain.; Drug: Papain 50 µg; The area will be exposed to 50 µg of papain.; Drug: Papain 100 µg; The area will be exposed to 100 µg of papain.; Other: Vehicle; The area will be exposed to vehicle
Experimental: Papain SPT; Each forearm of the subject will be divided into two squared areas (4x4 cm). The provocations of three areas will be performed with 100 µg of papain by SPT lancets. To assess the potential importance of repeated pricks, papain will be applied by 1, 5 or 25 SPT pricks thought the skin. The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.	Drug: Papain 1 SPT; Papain will be applied by 1 SPT prick thought the skin; Drug: Papain 5 SPT; Papain will be applied by 5 SPT pricks thought the skin; Drug: Papain 25 SPT; Papain will be applied by 25 SPT pricks thought the skin; Other: Cowhage; The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Superficial blood perfusion	Superficial blood perfusion is measured by a Speckle contrast imager (FLPI, Moor Instruments, England).	15 minutes
Measuring itch intensity by computerized Visual Analog Scale Scoring	The subjects will rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable" and similarly for sensations of stinging/pricking and burning, both of which are frequently associated with the sensation of itch.	15 minutes
Measuring pain intensity by computerized Visual Analog Scale Scoring	The subjects will rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable".	15 minutes
Measuring Alloknesis	Alloknesis is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 milliNewton of force). This stimulator is applied 0.5 cm outside the area of itch provocation.	15 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of Cold Detection Thresholds (CDT)	The tests for thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature decreases 1°C per second from a starting temperature of 32°C until the subject perceives a temperature change (cold sensation) and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 0°C will be used.	15 minutes
Measurement of Heat Pain Thresholds (HPT)	The tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature raises 1°C per second from a starting temperature of 32°C until the subject detects a painful sensation and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 52°C will be used.	15 minutes
Measurement of Warm Detection Thresholds (WDT)	The tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature raises 1°C per second from a starting temperature of 32°C until the subject detects a painful sensation and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 52°C will be used.	15 minutes
Measurement of Pain to Supra-threshold Heat Stimuli	The tests will be conducted by using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. The subjects will have to rate the pain to two suprathreshold heat pain stimuli (starting and ending at 32°C with an increase and decrease of 5°C and 3 s plateau at 50°C).	15 minutes
Measurement of Mechanical Pain Sensitivity (MPS)	This test is conducted using a pin-prick set (Aalborg University, Aalborg).	15 minutes
Measurement of Cold Pain Thresholds (CPT)	The tests for thermal sensation will all be conducted using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device. A thermode stimulator of 3x3 cm will be placed on the treated/placebo areas and kept in place by means of Velcro tape. During the first 8 seconds, the temperature decreases 1°C per second from a starting temperature of 32°C until the subject perceives a temperature change (cold sensation) and presses a button that will terminate the measurement and return the temperature to baseline at a rate of 5°C /s. A cut-off temperature of 0°C will be used.	15 minutes
Measurement of Mechanical Pain Thresholds (MPT)	This test is conducted using a pin-prick set (Aalborg University, Aalborg).	15 minutes
Touch Pleasantness (TP)	Pleasant touch sensation measured using a standardized sensory brush (SENSELab Brush-05, Somedic AB, Hörby, Sweden) exerting a force of 200 to 400 mN.	15 minutes

Collaborators and Investigators

• Sponsor: Aalborg University
• Investigators: Principal Investigator: Silvia Lo Vecchio, Aallborg University

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2020
• Primary Completion (Actual): June 1, 2021
• Study Completion (Actual): June 1, 2021

Study Registration Dates

• First Submitted: August 13, 2020
• First Submitted That Met QC Criteria: August 13, 2020
• First Posted (Actual): August 17, 2020

Study Record Updates

• Last Update Posted (Actual): July 9, 2021
• Last Update Submitted That Met QC Criteria: July 8, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Other Study ID Numbers: N-20200005

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No